Last update: Aug. 7, 2019

Bevacizumab (intravitreal)

Very Low Risk for breastfeeding

Safe. Compatible.
Minimal risk for breastfeeding and infant.

A humanized monoclonal antibody (IgG1 immunoglobulin) produced by recombinant DNA technology.
It works by blocking the vascular endothelial growth factor.
Intravitreal administration is used in macular degeneration due to choroidal neovascularization.

It is excreted in breastmilk in clinically insignificant amounts (McFarland 2015, Ehlken 2012) and no problems have been observed in infants whose mothers had been given it (Mc Farland 2015, Tarantola 2010).

Intravitreal administration: the small dose and the minimal transfer to blood from the vitreous humor as well as there being no detected levels in breastmilk or side effects in infants make this type of administration safe during breastfeeding.

A study has recorded a 35% decrease in the concentration of vascular endothelial growth factor (VEGF) in breastmilk, without specifying problems in the infant, for this reason some authors recommend the use of ranibizumab which does not seem to decrease the concentration of VEGF (Ehlken 2012).

Given the strong existing evidence regarding the benefits of breastfeeding for the development of babies and the health of mothers, it is advisable to evaluate the risk-benefit of any maternal treatment, including chemotherapy, individually advising each mother who wishes to continue with breastfeeding (Koren 2013).

See below the information of this related product:


Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.


Bevacizumab (intravitreal) belongs to these groups or families:


Variable Value Unit
Oral Bioavail. 0 %
Molecular weight 149.000 daltons
Tmax 480 hours


  1. McFarland TJ, Rhoads AD, Hartzell M, Emerson GG, Bhavsar AR, Stout JT. BEVACIZUMAB LEVELS IN BREAST MILK AFTER LONG-TERM INTRAVITREAL INJECTIONS. Retina. 2015 Aug;35(8):1670-3. Abstract
  2. Koren G, Carey N, Gagnon R, Maxwell C, Nulman I, Senikas V; Society of Obstetricians and Gynaecologists of Canada. Cancer chemotherapy and pregnancy. J Obstet Gynaecol Can. 2013 Mar;35(3):263-278. Abstract Full text (link to original source) Full text (in our servers)
  3. Ehlken C, Martin G, Stahl A, Agostini HT. Reduction of vascular endothelial growth factor a in human breast milk after intravitreal injection of bevacizumab but not ranibizumab. Arch Ophthalmol. 2012 Sep;130(9):1226-7. Abstract Full text (link to original source) Full text (in our servers)
  4. Tarantola RM, Folk JC, Boldt HC, Mahajan VB. Intravitreal bevacizumab during pregnancy. Retina. 2010 Oct;30(9):1405-11. Abstract

Total visits


Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at

e-lactancia is a resource recommended by La Liga de la Leche, España from Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM